Especially in patients with very high Lp(a) levels and a residual high ASCVD risk despite maximally tolerated lipid lowering therapy, lipoprotein apheresis significantly reduces Lp(a) and most likely also ASCVD risk, although not investigated in an RCT [31, 32]. This evidence concerns the gene LPA and atherosclerosis.